Comparison of Hepatocellular Carcinoma in Hispanic and Non-Hispanic Patients

Joseph Asemota 1, 2, 3, Olubunmi Oladunjoye 3, 4, Atinuke Babalola 2, Ugonna Nwosu 2, Po-Hong S. Liu 5, 2, Adeolu O. Oladunjoye 6, Neisy Castro-Webb 5, 2, Rebecca A. Miksad 5, 7

1. Internal Medicine, Howard University Hospital, Washington DC, USA. 2. Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. 3. Clinical Anatomy, St. George’s University School of Medicine, True Blue, GRD. 4. Internal Medicine, Tower Health-Reading Hospital, West Reading, USA. 5. Internal Medicine, UT Southwestern Medical Center, Dallas, USA. 6. Critical Care Medicine, Boston Children’s Hospital, Boston, USA. 7. Epidemiology and Public Health, Boston University School of Medicine, Boston, USA. 8. Medicine, Boston University School of Medicine, Boston, USA. 9. Oncology, Flatiron Health, New York, USA

Corresponding author: Joseph Asemota, jia601@mail.harvard.edu

Abstract

Background: Hepatocellular carcinoma (HCC) is the fastest growing cancer in the United States. Studies have shown that compared to Blacks and non-Hispanic Whites, Hispanics have a higher HCC incidence and mortality rate. Most studies investigating HCC in Hispanics have been conducted utilizing data largely from the Western and Southern United States. These findings may, however, not be highly representative of Hispanics in the Northeast, given the nonhomogenous distribution and diversity of Hispanics across the United States.

Methods: Some 148 HCC patients diagnosed between 1996 and 2012 were identified from a tertiary center in the northeastern United States. Hispanic patients were randomly matched to non-Hispanic White patients by year of diagnosis. Patient characteristics, HCC risk factors, treatment, and outcome were recorded. A Kaplan-Meier (KM) plot with log-rank tests was used for survival analysis.

Results: Compared to non-Hispanic White patients (n=89), Hispanic HCC patients (n=59) were more likely to have chronic hepatitis C infection (69.5% vs. 38.2%, p < 0.01), alcoholic liver disease (57.3% vs. 21.4%, p = 0.04) and were less likely to have chronic hepatitis B infection (6.8% vs. 24.7%, p = 0.01), and private insurance (37.3% vs. 57.5%, p = 0.02). Hispanics were more likely to be diagnosed with an earlier stage disease (Barcelona Clinic Liver Cancer, BCLC stages A and B) compared to non-Hispanic patients (71.7% vs. 36.8%, p < 0.01) and were more likely to receive locoregional treatment. Although Hispanics trended towards improved overall survival, this finding did not hold when stratified by the BCLC stage.

Conclusion: Risk factors for HCC in the northeastern Hispanic population are like those found among Hispanics in other US regions. Other research suggests Hispanics are at increased risk for hepatic injury and HCC. However, HCC in this northeastern Hispanic population appears to be less aggressive (earlier stage and trend towards better overall survival) than non-Hispanics. Further research may be needed to identify potential differences by ethnic group for HCC risk factors, presentation, and outcomes.

Introduction

Hepatocellular carcinoma (HCC) is the most common liver cancer, and it carries a poor prognosis [1]. It accounts for over 85% of all primary liver cancer and remains the third leading cause of cancer death worldwide [2]. Despite the overall decline in the incidence of cancer globally, the incidence of HCC continues to rise and it is the fastest-growing cancer in the United States [3].

There is significant geographic and ethnic variability in HCC incidence and etiologic risk factors. Globally, the highest incidence rates are seen in Asia and Africa, while much lower rates are observed in Europe and North America [2-3]. In the United States, Hispanic populations have a 2.7 times higher incidence rate and a 9% higher death rate than the non-Hispanic White population [4].

Many of the studies investigating HCC in Hispanics have focused on the Western and Southern regions of the United States. However, the country of origin for Hispanics varies by region. Hispanics from Mexico are predominant in the United States overall, but in the northeast region, Hispanic persons of Puerto Rican origin are more common [5]. In 2010, more than half of the Puerto Rican population residing in the 50 States lived in the Northeast, with more than 1.5 million Puerto Ricans living within six of the nine New England states [5].
The Surveillance, Epidemiology, and End Results (SEER) database, which is a data source for many HCC studies, includes only 2 of 18 registries (Connecticut and New Jersey) from the northeastern area [6-7]. In contrast, 14 registries from the Southern and Western areas are included [8]. Due to the geographic heterogeneity of the Hispanic population, patient characteristics for the large Puerto Rican population in New England may not be well presented in current research. This is particularly important as the prevalence of hepatitis C virus (HCV), alcohol consumption, diabetes, metabolic syndrome, and some other factors that may impact HCC diagnosis, treatment, and outcomes differ by country of origin of Hispanics [9-14].

Few HCC studies have been conducted in the Northeast where 12.6% of the US Hispanic population and 55% of Hispanics of Puerto Rico origin reside [5, 15]. Specifically, in the greater Boston area, there are 4.8 million people, 484,000 of which are Hispanics (25.9% Puerto Rican). We sought to describe and compare HCC among Hispanic and non-Hispanic patients seen at a tertiary care center in Boston, Massachusetts, which has a catchment area in the Northeast that extends to Rhode Island and New Hampshire.

**Materials And Methods**

**Data sources**

Beth Israel Deaconess Medical Center (BIDMC) is a tertiary referral center in Boston, Massachusetts. Patients were identified from the BIDMC HCC Database, a multidisciplinary, longitudinal data repository of all patients with HCC evaluated at BIDMC since 1996. Patients with a presumed HCC diagnosis were identified through the BIDMC tumor registry as well as a search of hospital electronic databases by diagnostic codes (ICD-9 155.0 and ICD-10 C22). All patients were retrospectively confirmed by pathologic and/or imaging criteria as per National Comprehensive Cancer Network® (NCCN®) HCC Guidelines 2.2014. Data recorded for each patient were: demographics, comorbidities, HCC risk factors (underlying liver disease, metabolic syndrome), tumor characteristics, as well cancer treatments and outcomes. Trained physicians abstracted structured and unstructured data from the Electronic Medical Record which were supplemented by paper chart review when necessary. Data were verified by a second physician for quality control through random secondary abstraction (about 25% of patients) as well as through missing data evaluation. Any disagreements between abstractors were arbitrated by senior physicians (A.B. and R.M.).

**Inclusion criteria**

Patients in the database eligible for inclusion in this study were diagnosed with HCC from 1996 to 2012. All Hispanic patients diagnosed with HCC were included. For the control group, non-Hispanic White patients were randomly chosen from the database (n=822) in a 1:1.5 ratio matched by year of diagnosis. The ratio was chosen to maximize available data.

**Data abstraction methods**

Individuals were identified as Hispanics using one of the following established criteria [16]: 1) A report in the electronic medical records indicating Hispanic ethnicity; 2) Spanish being listed as the preferred language in the medical records; 3) Hispanic surname as defined by the 1990 Census Spanish list. Parents’ surname (maiden name for women) was used if different from the current surname.

Metabolic syndrome was defined by the presence of at least three of the following criteria: (1) obesity (body mass index > 30 kg/m2, (2) serum triglycerides > 150 mg/dL, (3) serum high-density lipoprotein < 50 mg/dL for females and < 40 mg/dL for males, (4) history of hypertension or use of antihypertensive medications, and (5) history of diabetes or use of insulin or hypoglycemic agents. Metabolic syndrome was deemed not evaluable if there were no data documented for two or more components [17].

For alcohol, IV drugs, and tobacco, documentation of past or present use constituted exposure, regardless of quantity. If the Child-Pugh Score (CP) was not documented, it was calculated from the available recorded components. Due to the small sample size, the Barcelona Clinic Liver Cancer (BCLC) staging was trichotomized for analytical purposes. The groups were structured in order to achieve optimal similarity between patients within each group. Early stage (stage A) and intermediate stage (stage B) are herein referred to as an earlier-stage disease. Stages C and D were grouped as a late-stage disease.

Survival was defined as the time from the date of diagnosis to the date of death, last follow-up, or February 2017, whichever came first.

**Statistical analysis**

Data were summarized with descriptive analysis. Hispanic and non-Hispanic patients were compared using chi-square tests and Mann-Whitney U tests. Median time to death was estimated using the Kaplan-Meier (KM) life test method and compared using log-rank tests. Significance was set as a two-tailed p value < 0.05. Analyses were performed with SAS 9.4 (SAS Institute, Cary, NC).

**Results**
Demographics

After matching, a total of 59 Hispanic and 89 non-Hispanic White HCC patients were included in this analysis. Baseline demographic characteristics are shown in Table 1. The median ages at diagnosis were 58.0 [range 39-84, interquartile range (IQR) 52-65 years] and 60.0 (range 24-87, IQR 52-71 years) for Hispanic and non-Hispanic Whites respectively. In our study cohort, 20.3% of Hispanic and 19.1% of non-Hispanic White HCC patients were below age 50. Hispanics (37.3%) were less likely to have private insurance when compared with the non-Hispanic White cohort (57.3%) (p = 0.02).

| Demographics | Hispanics (N=59) | Non-Hispanic Whites (N=89) | p-value |
|--------------|------------------|-----------------------------|---------|
| Age          |                  |                             |         |
| Mean age in years (SD) | 59.1 (9.9)       | 60.3 (13.4)                | 0.53    |
| Median age in years (IQR) | 58.0 (52, 65)   | 60.0 (52, 71)              | 0.36    |
| ≤ 50 years   | 12 (20.3)        | 17 (19.1)                  |         |
| > 50 years   | 47 (79.6)        | 72 (80.9)                  |         |
| [50–64 years]| 31 (52.5)        | 38 (42.7)                  |         |
| [≥ 65 years] | 16 (27.1)        | 34 (38.2)                  |         |
| Mean weight in kilogram (SD) | 28.9 (±5.5)    | 27.8 (±6.4)                | 0.01    |
| Gender       |                  |                             |         |
| Male         | 42 (71.2)        | 78 (87.6)                  | 0.01    |
| Female       | 17(28.8)         | 11 (12.4)                  |         |
| Insurance    |                  |                             |         |
| Public/none  | 37 (62.7)        | 38 (42.7)                  | 0.01    |
| Private      | 22 (37.3)        | 51 (57.3)                  |         |
| Social habits|                  |                             |         |
| Alcohol      | 43 (72.9)        | 55 (61.8)                  | 0.16    |
| Tobacco      | 28 (47.5)        | 47 (52.8)                  | 0.52    |
| IVDU         | 16 (27.1)        | 16 (18.0)                  | 0.19    |
| Metabolic syndrome components |              |                             |         |
| Hypertension | 31 (52.5)        | 37 (42.1)                  | 0.21    |
| Diabetes mellitus | 26 (44.1)   | 31 (35.2)                  | 0.28    |
| Obesity*     | 19 (38.6)        | 17 (25.8)                  | 0.14    |
| Hypertriglyceridemia* | 16 (57.1) | 11 (47.8) | 0.51 |
| Low HDL*     | 15 (50.0)        | 9 (37.5)                   | 0.36    |
| Metabolic syndrome (N=82) |          |                             |         |
| Yes          | 17 (46.0)        | 12 (26.7)                  | 0.07    |
| No           | 20 (54.1)        | 33 (73.3)                  |         |
| Liver disease etiology |              |                             |         |
| Hepatitis B  | 4 (6.8)          | 22 (24.7)                  | 0.01    |
| Hepatitis C  | 41 (69.5)        | 34 (38.2)                  | <0.01   |
| Alcohol      | 22 (37.3)        | 19 (21.4)                  | 0.04    |
| AFP at diagnosis |            |                             |         |
| ≥ 400        | 4 (6.9)          | 26 (30.6)                  | <0.01   |
Liver disease risk factors

Metabolic syndrome

Due to missing data, only 82 individuals (37 Hispanics and 45 non-Hispanic Whites) were evaluated for metabolic syndrome (Table 2). The overall prevalence of metabolic syndrome was 46.0% amongst Hispanic and 26.7% for non-Hispanic Whites (p = 0.07).

| Number of positive components | N (%) |
|-------------------------------|-------|
| None                          | 28 (34.2%) |
| 1                             | 10 (12.2%) |
| 2                             | 15 (18.3%) |
| 3                             | 21 (25.6%) |
| 4                             | 7 (8.5%) |
| 5                             | 1 (1.2%) |

TABLE 2: Metabolic syndrome components.

Hepatocellular carcinoma diagnosis and treatment

Hispanics were more likely to be diagnosed with an earlier-stage HCC (71.7% vs. 36.8%, p < 0.01). They were generally more likely to receive loco-regional treatment (radiofrequency ablation (RFA), trans-arterial chemoembolization (TACE), cyberknife) compared to non-Hispanic Whites. A greater proportion of Hispanic patients than non-Hispanic Whites received RFA (40.7% vs. 21.4%, p = 0.02) and TACE (30.5% vs. 5.4%, p < 0.01). There were no significant differences between both groups in their likelihood for undergoing surgical resection (11.9% vs. 16.9%, p = 0.48), liver transplantation (23.7% vs. 13.5%, p = 0.11), or systemic therapy (25.4% vs. 30.3%, p = 0.52).

The overall median survival was 13 months (IQR 3-42 months) for non-Hispanic Whites and 33 months (IQR 9, 136 months) for Hispanics (p = 0.053) (Figure 1). The probability of survival at one and five years was higher (66.8% and 33.2%) for Hispanic than for non-Hispanic Whites (55.8% and 18.1%) (Figure 1). In non-Hispanic Whites, there was a longer median survival for those who presented at earlier stages (BCLC stages B and C) compared to those who presented at later stages (BCLC stages 0-1). The overall probability of survival was 71.7% at one year and 36.8% at five years (p < 0.01).

The overall 1-year and 5-year survival rates were 71.7% and 36.8%, respectively (p < 0.01). The survival rate for Hispanics was higher than that for non-Hispanic Whites at both one and five years. The median survival time was 13 months (IQR 3-42 months) for non-Hispanic Whites and 33 months (IQR 9, 136 months) for Hispanics (p = 0.053).

IVDU, intravenous drug use; TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation; AFP, alpha fetoprotein; HDL, high density lipoprotein; BCLC, Barcelona Clinic Liver Cancer.
A and B) compared to later stages of HCC (BCLC stages C and D) (43 vs. 7 months, p < 0.01) (Figure 2B). There was however no significant difference in the median survival by ethnicity when stratified by stage at presentation (Figure 3). Among nondiabetic patients, there was a significant difference in the median survival (Hispanics, 35 months and non-Hispanics, 13 months; p = 0.01, Figure 4A).

FIGURE 1: Plot comparing probability of survival of Hispanic and non-Hispanic patients with HCC.

HCC, hepatocellular carcinoma

FIGURE 2: Plot comparing probability of survival by staging in Hispanic (A) and non-Hispanic (B) patients.
Discussion

Overall median survival in this cohort of northeastern Hispanics was longer compared to non-Hispanics and Hispanic Whites had a higher prevalence of HCV and alcoholic liver disease. A higher prevalence of alcoholic liver disease was observed despite no difference in the documented use of alcohol between Hispanic and non-Hispanic Whites. Together, these findings suggest a susceptibility to the hepatotoxic effects of alcohol and its metabolites among Hispanics but a more indolent HCC disease course. Although some studies have evaluated potential mechanisms, little is known about susceptibility to liver damage in Hispanics [18-19].

Our real-world evidence from a unique population in the Northeast expands knowledge about the factors influencing the incidence of and outcomes for HCC in Hispanic patients. Further evidence that suggests an increased susceptibility for hepatic injury among Hispanics is that, with alcohol consumption, Hispanics tend to have about a two-fold greater increase in aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (γ-GGT) than non-Hispanics [18]. In addition, in nonalcoholic fatty liver disease (NAFLD), hepatocyte ballooning, and formation of Mallory bodies have been shown to develop more rapidly in Hispanics [19]. A plausible explanation for the observed effect of alcohol in the Hispanic subpopulation might be the PNPLA3 gene (a genetic variant associated with increased liver fat independent of differences in body composition, diabetes or serum lipoprotein levels, and known to influence fibrogenesis related to alcoholic steatohepatitis and viral hepatitis), which occurs more commonly in Hispanics [20]. Hispanics have a higher prevalence of obesity, with increased proportions of body fat compared to total body water and this body anthropometry in Hispanics may contribute to the underlying mechanism resulting in the attainment of higher blood alcohol concentrations, ultimately leading to greater toxicity [21]. Collectively, total body fat content with the accompanying reduction in total body water, as well as PNPLA3 genetic variation might explain the greater hepatic injury susceptibility and risk of HCC among Hispanics.

Furthermore, metabolic syndrome is known to be associated with HCC [22-24] and this was seen to be more prevalent among our Hispanic cohort (46.0% vs. 26.7%). This finding is in keeping with the National Health and Nutrition Examination Survey (NHANES) data, and other studies which observed that the highest
prevalence of metabolic syndrome in the United States population was within the Hispanic population [23]. Many cases of HCC without traditional risk factors are now widely attributed to metabolic syndrome [23]. A large population-based study demonstrated that pre-existing metabolic syndrome independently increased HCC risk 2.13 times [22]. Another study showed that having two components of metabolic syndrome increased the risk of HCC four-fold and each additional component increased the risk exponentially [24]. In addition, the co-existence of some of these metabolic risks with other known risk factors also has multiplicative effects. For example, co-existing obesity in chronic HBV and HCV positive patients has been associated with up to a 100-fold increased risk in HCC incidence and overall mortality [26].

The results from this study are largely in concordance with results found in other Hispanic-based HCC studies within the northeastern region and other parts of the United States. Our results suggest that compared to Non-Hispanic Whites, there is a higher prevalence of HCV infection among Hispanics (p < 0.01), which is similar to results reported by Guerrero-Preston et al. in their study looking at the risk factors for HCC among Hispanics in New York City [8]. Likewise, in a study by Wasley et al., Hispanics were shown to have a lower prevalence of HBV infection than non-Hispanic persons as was also observed in our study [27].

Finally, our analysis showed that Hispanics were less likely to have markedly elevated alpha-fetoprotein levels at the time of diagnosis of HCC. The lower levels of alpha-fetoprotein, which is often used as an early biomarker and adjunct in the diagnosis of HCC, is consistent with the finding of our Hispanic cohort being more likely to be diagnosed with earlier-stage disease. Even though previous research studies have demonstrated that Hispanics with non-alcoholic fatty liver disease have disproportionately more advanced fibrosis, cirrhosis, or HCC compared with non-Hispanics, the evidence on the comparative risk and progression of advanced liver disease and HCC in Hispanics with HCV infection remains inconclusive [28-29] and our result findings suggest a less aggressive progression of HCV-related HCC in Hispanics compared to non-Hispanic Whites. The lack of marked elevation in alpha-fetoprotein levels in Hispanics may itself be a pointer to a less active and aggressive progression of HCV-related HCC in Hispanics. More longitudinal and ethnico-racial studies will, however, be needed to tease out the nuances and confirm this hypothesis. Hispanics were more likely to receive loco-regional therapy such as RFA and TACE, which are often used as palliative treatment options in patients with advanced disease in whom tumor resection is not feasible or as a bridge to liver transplantation [30-32].

Explanations for this observation might include patient-related and physician-related barriers to treatment [33]. Patient-related barriers such as personal and cultural beliefs about treatment options, as well as lower socioeconomic status and level of education could result in treatment misconceptions, which would ultimately delay early treatment initiation [33-34]. Also, physician perceptions of patient preferences, inadequate treatment work-up, immunologic mismatching of human leukocyte antigens (HLA) status, and/or delays in referral can hinder early treatment initiation [33-34].

Limitations of the study
There are several limitations to our study. First, due to the retrospective nature of our data, this study has some important limitations and thus the results should be interpreted cautiously. Second, the relatively small sample size, and the fact that our study population was drawn from a database obtained from a single center may impose limitations on the generalizability of the study findings. As a consequence of the small sample size, stratification of patients into subgroups was restricted. Third, patient ethnicities were self-identified as documented in the medical records and, as such, the veracity could not be ascertained. We also did not evaluate the effect of secondary insurance. In light of these limitations, more prospective studies are, therefore, needed to confirm the results of this study.

Despite these limitations, the study highlights the risk factors and assesses the role that these factors may play in the development of HCC among specific Hispanic populations in the northeastern United States.

Conclusions
In conclusion, there is a disparately higher burden of hepatocellular cancer amongst Hispanics. The risk factors of HCC in the Hispanic subpopulation resident in the northeast region of the United States are largely similar to those found among Hispanics in other regions of the United States. While Hispanics show an increased susceptibility for hepatic injury and HCC, the progression of HCV-related HCC in this subpopulation appears to be less aggressive. Further research may be needed to identify potential differences by ethnic group for HCC risk factors, presentation, and outcomes.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influe

References

1. Dong C, Yoon YH, Chen CM, Yi HY: Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs. 2011, 72:892-902. 10.15288/jsad.2011.72.892

2. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015, 136:E359-E386. 10.1002/ijc.29210

3. El-Serag HB, Kanwal F: Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology. 2014, 60:1767-1775. 10.1002/hep.27222

4. Harrison AF, Ghanta R, Carrasquillo O, Martin P: Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol. 2011, 9:834-41; quiz e109-e110. 10.1016/j.cgh.2011.04.027

5. The Hispanic Population: 2010. (2011). Accessed: January 22, 2021: https://www.census.gov/content/dam/Census/library/publications/2011/dec/c2010br-04.pdf.

6. Ha J, Yan M, Aguilar M, et al.: Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016, 122:2512-2523. 10.1002/cncr.30105

7. Albrekke SF, Henley SJ, Cucinelli JE, McGlynn KA: Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014, 109:542-553. 10.1038/ajg.2014.11

8. About the SEER Registries. (2018). Accessed: 2 February, 2018: https://seer.cancer.gov/registries/index.html

9. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999, 341:556-562. 10.1056/NEJM199908193410802

10. Pyszspoulnou N, Jefferies L: Hepatitis C in African Americans. J Clin Gastroenterol. 2007, 41:185-195. 10.1097/01.mcg.0000225689.60255.44

11. Heiss G, Snyder ML, Teng Y, et al.: Prevalence of metabolic syndrome among Hispanics/Latinos of diverse background: the Hispanic Community Health Study/Study of Latinos. Diabetes Care. 2014, 37:2359-2359. 10.2337/dc15-2505

12. Kunihoth MJ, Jung M, Everhart JE, et al.: Prevalence of hepatitis C virus infection in US Hispanic/Latino adults: results from the NHANES 2007-2010 and HCHS/SOL studies. J Infect Dis. 2014, 209:1358-1359.

13. Schniedermaer N, Llibre M, Cowie CC, et al.: Prevalence of diabetes among Hispanics/Latinos from diverse backgrounds: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Diabetes Care. 2014, 37:2323-2329. 10.2337/dc13-2959

14. Velasco-Mondragon E, Jimenez A, Palladino-Davis AG, Davis D, Escamilla-lluego JA: Hispanic health in the USA: a scoping review of the literature. Public Health Rev. 2016, 37:31. 10.1186/s40985-016-0045-2

15. Hispanic Map of the United States 2017. (2017). Accessed: January 22, 2021: http:// cervantesobservatorio.fas.harvard.edu/sites/default/files/hispanic_map_2017en.pdf.

16. Coronado GD, Koepsell TD, Thompson B, et al.: Assessing cervical cancer risk in Hispanics. Cancer Epidemiol Biomark Prev. 2002, 11:979-984.

17. Alberti KG, Zimmer P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006, 23:469-480. 10.1111/j.1464-5491.2006.01585.x

18. Stewart SH: Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med. 2002, 162:2236-2239. 10.1001/archinte.162.19.2236

19. Mohanty SR, Troy TN, Hsu D, O'Brien BL, Jensen DM, Hart J: Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009, 50:797-804. 10.1053/j.jhep.2008.11.017

20. Dongiovanni P, Donati B, Lombardi R, Mancina RM, Romeo S, Valenti L: PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013, 19:6969-6978. 10.3748/wjg.v19.i41.6969

21. Chartbook on Trends in the Health of Americans. (2003). Accessed: 2 February, 2018: https://www.cdc.gov/nchs/products/pubs/pubd/hestat/trendshealth03/trendshealth03.htm

22. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA: Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011, 54:465-471. 10.1002/hep.23579

23. Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA: Primary hepatocellular carcinoma and metabolic syndrome: an update. World J Gastrointest Oncol. 2013, 5:186-194. 10.4251/wjgo.v5.i9.186

24. Turati F, Talatimi R, Pelucchi C, et al.: Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2015, 108:222-228. 10.1038/bjc.2012.492

25. Moore JX, Chaudhary N, Akinyemiju T: Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis. 2017, 14:E24. 10.5888/pcd14.160287

26. Chen CL, Yang HI, Yang WS, et al.: Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008, 135:111-121. 10.1053/j.gastro.2008.03.073

27. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B: The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010, 202:192-201. 10.1086/653622

28. Lomonoño B, Ortiz-Lopez C, Orsak B, et al.: Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011, 54:837-845. 10.1002/hep.24485

29. El-Serag HB, Kramer J, Duan Z, Kanwal F: Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014, 109:1427-1455. 10.1038/ajg.2014.214

30. Mazzaferrro V, Battiston C, Perrone S, et al.: Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004, 240:900-909.
31. Yeh MM, Yeung RS,Apisarnthanarax S, et al.: Multidisciplinary perspective of hepatocellular carcinoma: a Pacific Northwest experience. World J Hepatol. 2015, 7:1460-1483. 10.4254/wjh.v7.i11.1460

32. Asemota J, Saleh M, Ighinovia O, Burns Jr.: A concise review on current trends in imaging and surgical management of hepatocellular carcinoma. Cureus. 2020, 12:e9191. 10.7759/cureus.9191

33. Yu JC, Neugut AI, Wang S, et al.: Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer. 2010, 116:1801-1809. 10.1002/cncr.24936

34. Eckhoff DE, McGuire BM, Young CI, et al.: Race: a critical factor in organ donation, patient referral and selection, and orthotopic liver transplantation?. Liver Transpl Surg. 1998, 4:499-505. 10.1002/lt.500040606